ALS News Today Home | ALS News Today
网页S-oxprenolol, an investigational therapy being developed by Actimed Therapeutics to treat muscle wasting in amyotrophic lateral sclerosis (ALS), has been granted orphan drug status in the U.S. That designation, awarded by the U.S. Food and Drug Administration, is given to therapies intended to treat rare diseases, like ALS, that….
ALS News Today
网页ALS News Today. Recent Posts. Why I chose to continue learning after my ALS diagnosis. Initiative aims to improve ALS research, clinical trial access. MDA seeks applications for advocacy collaboration grants. Over 420 ‘Fill the Boot’ events in US to raise funds for MDA.
News Archives - ALS News Today
网页The U.S. Food and Drug Administration (FDA) has given the green light to Dr.Noah Biotech to initiate a Phase 1 clinical trial of NDC-011, a combination therapy for amyotrophic lateral sclerosis (ALS), in healthy volunteers. The trial, planned for the first half of 2025 at a single site…. September 11, 2024 News by Andrea Lobo, PhD.
Top 10 ALS Stories of 2021 - ALS News Today
网页No. 1 — “ Global Phase 3 Trial of AMX0035 to Enroll 600 ALS Patients, Amylyx Says”. Our most-read article of 2021 concerned the PHOENIX Phase 3 trial (NCT05021536), which was launched to confirm the positive results from the CENTAUR trial. Amylyx announced that PHOENIX would enroll up to 600 people with ALS diagnosed within the last two ...
Research that will explore causes of sporadic ALS wins $100K grant
网页17 小时之前 · Amprion has been awarded a $100,000 research grant to support studies on the causes of sporadic amyotrophic lateral sclerosis (ALS) that could help diagnose and develop potential therapies for the disease. The project, led by Richard Smith, MD, state director of the Center for Neurologic Study, and Amprion’s co …
Higher risk of ALS found for rare gene variants tied to Parkinson's
网页3 天之前 · Investigating rare genetic variants that may raise the risk of ALS. The exact causes of ALS are unclear, but there’s strong evidence that a person’s genetic makeup has an impact on the risk of developing the disease. While mutations are mostly found in people with familial ALS, about 10% of those with sporadic ALS …
Phase 3 trial of oral pridopidine in treating ALS likely this year
网页2024年1月29日 · The Phase 2/3 pridopidine arm (NCT04615923) enrolled 163 adults with clinically possible, probable, or definite ALS, whose symptoms had started within the last three years. Participants were randomly assigned to oral pridopidine (45 mg) or a matched placebo taken twice daily for 24 weeks, or about six months. This was followed by …
Amyotrophic Lateral Sclerosis (ALS) Treatment - ALS News Today
网页2024年4月11日 · Riluzole formulations. Riluzole was the first treatment to be approved for ALS by the FDA in 1995. The therapy is thought to work by reducing molecular signaling, which can overstimulate and damage nerve cells. The original formulation of riluzole is an oral tablet marketed under the brand name Rilutek by Covis Pharma.
Man controls Alexa with thoughts via brain-computer interface
网页1 天前 · The 64-year-old man, identified in a Synchron press release as Mark, lost the function of his upper limbs due to ALS. He was implanted with the BCI as part of a clinical trial. While control of Alexa devices typically involves the ability to tap a screen or speak, Mark is able to use his thoughts to directly control his smart home via the Tap to Alexa feature on an Amazon Fire tablet, Synchron ...
ALS Groups Give $1.1M More in Support of T-cell Therapy in …
网页2021年4月1日 · The ALS Association, Muscular Dystrophy Association (MDA), and ALS Finding a Cure have given an additional $1.1 million to support work on a cell therapy — now in a Phase 2 trial — that could slow the progression of amyotrophic lateral sclerosis (ALS).. This award supplements the $2.4 million these three nonprofits initially gave to help launch the ongoing study into regulatory T-cells, a ...
跳至内容